ArticleMovement disorders clinical practice2024
Motor Complications in Parkinson's Disease: Results from 3343 Patients Followed for up to 12 Years.
Article in Movement disorders clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Trial
- Comparative efficacy of Mucuna pruriens and conventional levodopa in Parkinson's disease: a randomized controlled trial on pharmacokinetics and clinical perspectives from Asia.Journal of neural transmission (Vienna, Austria : 1996) · 2025Trial
- Frequency and types of motor fluctuations in patients presenting with advanced Parkinson's disease.Pakistan journal of medical sciences · 2026Article
- Levodopa-Induced dyskinesia in Latin America: Prevalence and associated clinical factors in the LARGE-PD cohort.Journal of Parkinson's disease · 2026Article
- Levodopa-entacapone-carbidopa intestinal gel in advanced Parkinson's disease: an analysis of interim data for Romanian patients enrolled in the ELEGANCE study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Tracking Motor Progression and Device-Aided Therapy Eligibility in Parkinson's Disease.Annals of clinical and translational neurology · 2026Article
- Relationship between frailty and disease progression in Parkinson's disease: a 3-year longitudinal study.GeroScience · 2026Article
- COMT inhibition with entacapone for patients with Parkinson's disease and motor complications: the novelty of continuous infusion.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Onset of Motor Complications and Medication Dose in Newly Diagnosed and Treated Parkinson's Disease.Parkinson's disease · 2026Article
- Timing of device-aided therapy initiation in Parkinson's disease: reference estimates for healthcare planning and biological heterogeneity.Clinical parkinsonism & related disorders · 2026Article
- Pharmacotherapy in Early Parkinson's Disease: A Pragmatic Approach.Annals of Indian Academy of Neurology · 2025Article
- A Podcast on the Rhythms of Healing: Patient and Physician Insights on Art, Music, Dance Therapy and Creativity in Parkinson's Disease.Neurology and therapy · 2025Article
- Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson's disease.Clinical parkinsonism & related disorders · 2025Review
- Occurrence of Motor Complications and Gait Problems After Introduction of Medical Treatment in Parkinson's Disease.Parkinson's disease · 2025Article
- Early start of opicapone in Parkinson's disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuations.Frontiers in neurology · 2025Article
- CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.EClinicalMedicine · 2024Article
- Evaluating the Effects of Frequency of Subthalamic Nucleus Deep Brain Stimulation on Postural Control in Parkinson's Disease: A Case-Series Study.Journal of clinical medicine · 2024Article
- No association between genetically predicted vitamin D levels and Parkinson's disease.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMotor complications are well recognized in Parkinson's disease (PD), but their reported prevalence varies and functional impact has not been well studied.
objectivesTo quantify the presence, severity, impact and associated factors for motor complications in PD.
methodsAnalysis of three large prospective cohort studies of recent-onset PD patients followed for up to 12 years. The MDS-UPDRS part 4 assessed motor complications and multivariable logistic regression tested for associations. Genetic risk score (GRS) for Parkinson's was calculated from 79 single nucleotide polymorphisms.
results3343 cases were included (64.7% male). Off periods affected 35.0% (95% CI 33.0, 37.0) at 4-6 years and 59.0% (55.6, 62.3) at 8-10 years. Dyskinesia affected 18.5% (95% CI 16.9, 20.2) at 4-6 years and 42.1% (38.7, 45.5) at 8-10 years. Dystonia affected 13.4% (12.1, 14.9) at 4-6 years and 22.8% (20.1, 25.9) at 8-10 years. Off periods consistently caused greater functional impact than dyskinesia. Motor complications were more common among those with higher drug doses, younger age at diagnosis, female gender, and greater dopaminergic responsiveness (in challenge tests), with associations emerging 2-4 years post-diagnosis. Higher Parkinson's GRS was associated with early dyskinesia (0.026 ≤ P ≤ 0.050 from 2 to 6 years).
conclusionsOff periods are more common and cause greater functional impairment than dyskinesia. We confirm previously reported associations between motor complications with several demographic and medication factors. Greater dopaminergic responsiveness and a higher genetic risk score are two novel and significant independent risk factors for the development of motor complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.